Xuhong Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xuhong Hou has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Weiping Jia
State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
11 shared publications Li Wei
Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
8 shared publicationsYebei Liang
Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
7 shared publicationsKeqing Dong
General Practitioner Teams in Community Health Service Center of Nicheng, Pudong New District Shanghai China
6 shared publicationsYuqian Bao
Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
6 shared publicationsFusong Jiang
Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
5 shared publications
Latest Publications
- Open Access
- 4 November 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (6) , e70093
Effect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China
Background: Understanding the relationship between relative skeletal muscle mass and newly proposed steatotic liver disease (SLD) is crucial, but research gaps still exist. Based on a cohort study, we investigated the impact of relative skeletal muscle mass on incident SLD and its subtypes and explored potential mediators involved in these relationships. Methods: We followed 1964 subjects aged 55–70 years (median age: 61.4 [58.4–65.1] years; 45.5% male participants). Appendicular skeletal muscle mass (ASM) was measured using bioelectrical impedance analysis and adjusted for height squared (ASM/height 2 ), weight (ASM/weight) and body mass index (ASM/BMI) to quantify relative skeletal muscle mass. SLD was diagnosed using ultrasonography and classified into metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol‐associated liver disease (MetALD) and alcohol‐associated liver disease (ALD). Results: Over a mean 4.3‐year follow‐up period, 598 participants (30.4%) developed SLD: 539 MASLD (27.4%), 38 MetALD (1.9%) and 21 ALD (1.1%). Higher ASM/weight and ASM/BMI were associated with lower risks of SLD and MASLD (RR per SD [95% CI]: 0.71 [0.61–0.82], 0.59 [0.46–0.76]; 0.66 [0.58–0.76], 0.51 [0.40–0.64]; all p < 0.001). Associations of ASM/height 2 with SLD and MASLD shifted from positive to negative after adjustment for BMI (from 1.67 [1.51–1.84] to 0.77 [0.67–0.89]; from 2.30 [1.92–2.76] to 0.61 [0.47–0.79], all p < 0.001). ASM/height 2 and ASM/weight were negatively associated with MetALD (0.49 [0.26–0.94], p = 0.031; 0.50 [0.27–0.93], p = 0.029), whereas ASM/BMI was inversely associated with ALD (0.40 [0.18–0.88], p = 0.023). The effects of ASM/height 2 , ASM/weight and ASM/BMI on incident MASLD were partially mediated by adiponectin (percentage mediated [95% CI]: 6.3% [2.5%–11.1%]; 9.4% [5.0%–14.6%]; 9.5% [5.1%–15.5%]), uric acid (4.7% [1.6%–8.9%]; 5.3% [2.6%–8.5%]; 5.3% [2.4%–8.8%]), triglyceride (7.1% [3.9%–11.1%]; 7.5% [4.4%–10.9%]; 8.7% [5.3%–13.4%]) and homeostasis model assessment of insulin resistance (13.9% [9.5%–20.4%]; 15.0% [10.0%–20.2%]; 14.5% [9.9%–20.7%]). The effects of ASM/weight and ASM/BMI on incident MASLD were mediated by cholinesterase (8.2% [3.6%–13.1%]; 10.5% [6.1%–16.3%]), prealbumin (6.2% [2.9%–9.8%]; 6.0% [3.0%–10.1%]), retinol‐binding protein‐4 (5.4% [3.0%–8.5%]; 4.6% [1.9%–8.5%]) and osteocalcin (2.1% [0.1%–4.5%]; 2.9% [0.6%–5.7%]). Conclusions: Relative skeletal muscle mass adjusted for weight or BMI, rather than height alone, better reflects protective effects against SLD. Mediation analysis reveals key metabolic factors linking muscle mass and liver health, offering insights into the pathogenic pathways involved in muscle–liver crosstalk.
- 4 November 2025
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (6) , e70093
Open AccessEffect of Skeletal Muscle Mass and Its Associated Mediators on the Development of Steatotic Liver Disease: A Cohort Study in China
Background: Understanding the relationship between relative skeletal muscle mass and newly proposed steatotic liver disease (SLD) is crucial, but research gaps still exist. Based on a cohort study, we investigated the impact of relative skeletal muscle mass on incident SLD and its subtypes and explored potential mediators involved in these relationships. Methods: We followed 1964 subjects aged 55–70 years (median age: 61.4 [58.4–65.1] years; 45.5% male participants). Appendicular skeletal muscle mass (ASM) was measured using bioelectrical impedance analysis and adjusted for height squared (ASM/height 2 ), weight (ASM/weight) and body mass index (ASM/BMI) to quantify relative skeletal muscle mass. SLD was diagnosed using ultrasonography and classified into metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol‐associated liver disease (MetALD) and alcohol‐associated liver disease (ALD). Results: Over a mean 4.3‐year follow‐up period, 598 participants (30.4%) developed SLD: 539 MASLD (27.4%), 38 MetALD (1.9%) and 21 ALD (1.1%). Higher ASM/weight and ASM/BMI were associated with lower risks of SLD and MASLD (RR per SD [95% CI]: 0.71 [0.61–0.82], 0.59 [0.46–0.76]; 0.66 [0.58–0.76], 0.51 [0.40–0.64]; all p < 0.001). Associations of ASM/height 2 with SLD and MASLD shifted from positive to negative after adjustment for BMI (from 1.67 [1.51–1.84] to 0.77 [0.67–0.89]; from 2.30 [1.92–2.76] to 0.61 [0.47–0.79], all p < 0.001). ASM/height 2 and ASM/weight were negatively associated with MetALD (0.49 [0.26–0.94], p = 0.031; 0.50 [0.27–0.93], p = 0.029), whereas ASM/BMI was inversely associated with ALD (0.40 [0.18–0.88], p = 0.023). The effects of ASM/height 2 , ASM/weight and ASM/BMI on incident MASLD were partially mediated by adiponectin (percentage mediated [95% CI]: 6.3% [2.5%–11.1%]; 9.4% [5.0%–14.6%]; 9.5% [5.1%–15.5%]), uric acid (4.7% [1.6%–8.9%]; 5.3% [2.6%–8.5%]; 5.3% [2.4%–8.8%]), triglyceride (7.1% [3.9%–11.1%]; 7.5% [4.4%–10.9%]; 8.7% [5.3%–13.4%]) and homeostasis model assessment of insulin resistance (13.9% [9.5%–20.4%]; 15.0% [10.0%–20.2%]; 14.5% [9.9%–20.7%]). The effects of ASM/weight and ASM/BMI on incident MASLD were mediated by cholinesterase (8.2% [3.6%–13.1%]; 10.5% [6.1%–16.3%]), prealbumin (6.2% [2.9%–9.8%]; 6.0% [3.0%–10.1%]), retinol‐binding protein‐4 (5.4% [3.0%–8.5%]; 4.6% [1.9%–8.5%]) and osteocalcin (2.1% [0.1%–4.5%]; 2.9% [0.6%–5.7%]). Conclusions: Relative skeletal muscle mass adjusted for weight or BMI, rather than height alone, better reflects protective effects against SLD. Mediation analysis reveals key metabolic factors linking muscle mass and liver health, offering insights into the pathogenic pathways involved in muscle–liver crosstalk.
- Open Access
- 20 January 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (1) , 66
Osteopenia Metabolomic Biomarkers for Early Warning of Osteoporosis
Introduction: This study aimed to capture the early metabolic changes before osteoporosis occurs and identify metabolomic biomarkers at the osteopenia stage for the early prevention of osteoporosis. Materials and Methods: Metabolomic data were generated from normal, osteopenia, and osteoporosis groups with 320 participants recruited from the Nicheng community in Shanghai. We conducted individual edge network analysis (iENA) combined with a random forest to detect metabolomic biomarkers for the early warning of osteoporosis. Weighted Gene Co-Expression Network Analysis (WGCNA) and mediation analysis were used to explore the clinical impacts of metabolomic biomarkers. Results: Visual separations of the metabolic profiles were observed between three bone mineral density (BMD) groups in both genders. According to the iENA approach, several metabolites had significant abundance and association changes in osteopenia participants, confirming that osteopenia is a critical stage in the development of osteoporosis. Metabolites were further selected to identify osteopenia (nine metabolites in females; eight metabolites in males), and their ability to discriminate osteopenia was improved significantly compared to traditional bone turnover markers (BTMs) (female AUC = 0.717, 95% CI 0.547–0.882, versus BTMs: p = 0.036; male AUC = 0.801, 95% CI 0.636–0.966, versus BTMs: p = 0.007). The roles of the identified key metabolites were involved in the association between total fat-free mass (TFFM) and osteopenia in females. Conclusion: Osteopenia was identified as a tipping point during the development of osteoporosis with metabolomic characteristics. A few metabolites were identified as candidate early-warning biomarkers by machine learning analysis, which could indicate bone loss and provide new prevention guidance for osteoporosis.
- 20 January 2025
- Published by MDPI AG in Metabolites
- Vol. 15 (1) , 66
Open AccessOsteopenia Metabolomic Biomarkers for Early Warning of Osteoporosis
Introduction: This study aimed to capture the early metabolic changes before osteoporosis occurs and identify metabolomic biomarkers at the osteopenia stage for the early prevention of osteoporosis. Materials and Methods: Metabolomic data were generated from normal, osteopenia, and osteoporosis groups with 320 participants recruited from the Nicheng community in Shanghai. We conducted individual edge network analysis (iENA) combined with a random forest to detect metabolomic biomarkers for the early warning of osteoporosis. Weighted Gene Co-Expression Network Analysis (WGCNA) and mediation analysis were used to explore the clinical impacts of metabolomic biomarkers. Results: Visual separations of the metabolic profiles were observed between three bone mineral density (BMD) groups in both genders. According to the iENA approach, several metabolites had significant abundance and association changes in osteopenia participants, confirming that osteopenia is a critical stage in the development of osteoporosis. Metabolites were further selected to identify osteopenia (nine metabolites in females; eight metabolites in males), and their ability to discriminate osteopenia was improved significantly compared to traditional bone turnover markers (BTMs) (female AUC = 0.717, 95% CI 0.547–0.882, versus BTMs: p = 0.036; male AUC = 0.801, 95% CI 0.636–0.966, versus BTMs: p = 0.007). The roles of the identified key metabolites were involved in the association between total fat-free mass (TFFM) and osteopenia in females. Conclusion: Osteopenia was identified as a tipping point during the development of osteoporosis with metabolomic characteristics. A few metabolites were identified as candidate early-warning biomarkers by machine learning analysis, which could indicate bone loss and provide new prevention guidance for osteoporosis.
- Top Cited PapersOpen Access
- 11 January 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 55, 101463
Prevalence of chronic kidney disease among Chinese adults with diabetes: a nationwide population-based cross-sectional study
- 11 January 2025
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 55, 101463
Top Cited PapersOpen AccessPrevalence of chronic kidney disease among Chinese adults with diabetes: a nationwide population-based cross-sectional study
- Open Access
- 6 January 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (1) , 101884
Associations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study
- 6 January 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (1) , 101884
Open AccessAssociations between multiple metabolic biomarkers with steatotic liver disease subcategories: A 5-year Chinese cohort study
- Open Access
- 30 November 2023
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 15 (11)
Sex- and age-specific associations between abdominal fat and non-alcoholic fatty liver disease: a prospective cohort study
Obesity is closely related to non-alcoholic fatty liver disease (NAFLD). Although sex differences in body fat distribution have been well demonstrated, little is known about the sex-specific associations between adipose tissue and the development of NAFLD. Using community-based cohort data, we evaluated the associations between magnetic resonance imaging quantified areas of abdominal adipose tissue, including visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), and incident NAFLD in 2830 participants (1205 males and 1625 females) aged 55–70 years. During a 4.6-year median follow-up, the cumulative incidence rates of NAFLD increased with areas of VAT and SAT both in males and in females. Further analyses showed that the above-mentioned positive associations were stronger in males than in females, especially in participants under 60 years old. In contrast, these sex differences disappeared in those over 60 years old. Furthermore, the risk of developing NAFLD increased non-linearly with increasing fat area in a sex-specific pattern. Additionally, sex-specific potential mediators, such as insulin resistance, lipid metabolism, inflammation, and adipokines, may exist in the associations between adipose tissue and NAFLD. This study showed that the associations between abdominal fat and the risk of NAFLD were stratified by sex and age, highlighting the potential need for sex- and age-specific management of NAFLD.
- 30 November 2023
- Published by Oxford University Press (OUP) in Journal of Molecular Cell Biology
- Vol. 15 (11)
Open AccessSex- and age-specific associations between abdominal fat and non-alcoholic fatty liver disease: a prospective cohort study
Obesity is closely related to non-alcoholic fatty liver disease (NAFLD). Although sex differences in body fat distribution have been well demonstrated, little is known about the sex-specific associations between adipose tissue and the development of NAFLD. Using community-based cohort data, we evaluated the associations between magnetic resonance imaging quantified areas of abdominal adipose tissue, including visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), and incident NAFLD in 2830 participants (1205 males and 1625 females) aged 55–70 years. During a 4.6-year median follow-up, the cumulative incidence rates of NAFLD increased with areas of VAT and SAT both in males and in females. Further analyses showed that the above-mentioned positive associations were stronger in males than in females, especially in participants under 60 years old. In contrast, these sex differences disappeared in those over 60 years old. Furthermore, the risk of developing NAFLD increased non-linearly with increasing fat area in a sex-specific pattern. Additionally, sex-specific potential mediators, such as insulin resistance, lipid metabolism, inflammation, and adipokines, may exist in the associations between adipose tissue and NAFLD. This study showed that the associations between abdominal fat and the risk of NAFLD were stratified by sex and age, highlighting the potential need for sex- and age-specific management of NAFLD.
- Open Access
- 3 May 2023
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 20 (1) , 1-9
Serum cholinesterase is associated with incident diabetic retinopathy: the Shanghai Nicheng cohort study
Serum cholinesterase (ChE) is positively associated with incident diabetes and dyslipidemia. We aimed to investigate the relationship between ChE and the incidence of diabetic retinopathy (DR). Based on a community-based cohort study followed for 4.6 years, 1133 participants aged 55–70 years with diabetes were analyzed. Fundus photographs were taken for each eye at both baseline and follow-up investigations. The presence and severity of DR were categorized into no DR, mild non-proliferative DR (NPDR), and referable DR (moderate NPDR or worse). Binary and multinomial logistic regression models were used to estimate the risk ratio (RR) and 95% confidence interval (CI) between ChE and DR. Among the 1133 participants, 72 (6.4%) cases of DR occurred. The multivariable binary logistic regression showed that the highest tertile of ChE (≥ 422 U/L) was associated with a 2.01-fold higher risk of incident DR (RR 2.01, 95%CI 1.01-4.00; P for trend < 0.05) than the lowest tertile (< 354 U/L). The multivariable binary and multinomial logistic regression showed that the risk of DR increased by 41% (RR 1.41, 95%CI 1.05–1.90), and the risk of incident referable DR was almost 2-fold higher than no DR (RR 1.99, 95%CI 1.24–3.18) with per 1-SD increase of loge-transformed ChE. Furthermore, multiplicative interactions were found between ChE and elderly participants (aged 60 and older; P for interaction = 0.003) and men (P for interaction = 0.044) on the risk of DR. In this study, ChE was associated with the incidence of DR, especially referable DR. ChE was a potential biomarker for predicting the incident DR.
- 3 May 2023
- Published by Springer Nature in Nutrition & Metabolism
- Vol. 20 (1) , 1-9
Open AccessSerum cholinesterase is associated with incident diabetic retinopathy: the Shanghai Nicheng cohort study
Serum cholinesterase (ChE) is positively associated with incident diabetes and dyslipidemia. We aimed to investigate the relationship between ChE and the incidence of diabetic retinopathy (DR). Based on a community-based cohort study followed for 4.6 years, 1133 participants aged 55–70 years with diabetes were analyzed. Fundus photographs were taken for each eye at both baseline and follow-up investigations. The presence and severity of DR were categorized into no DR, mild non-proliferative DR (NPDR), and referable DR (moderate NPDR or worse). Binary and multinomial logistic regression models were used to estimate the risk ratio (RR) and 95% confidence interval (CI) between ChE and DR. Among the 1133 participants, 72 (6.4%) cases of DR occurred. The multivariable binary logistic regression showed that the highest tertile of ChE (≥ 422 U/L) was associated with a 2.01-fold higher risk of incident DR (RR 2.01, 95%CI 1.01-4.00; P for trend < 0.05) than the lowest tertile (< 354 U/L). The multivariable binary and multinomial logistic regression showed that the risk of DR increased by 41% (RR 1.41, 95%CI 1.05–1.90), and the risk of incident referable DR was almost 2-fold higher than no DR (RR 1.99, 95%CI 1.24–3.18) with per 1-SD increase of loge-transformed ChE. Furthermore, multiplicative interactions were found between ChE and elderly participants (aged 60 and older; P for interaction = 0.003) and men (P for interaction = 0.044) on the risk of DR. In this study, ChE was associated with the incidence of DR, especially referable DR. ChE was a potential biomarker for predicting the incident DR.
- Open Access
- 16 March 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (7) , 100730
A greater ratio of thigh subcutaneous fat to abdominal fat is associated with protection against non-alcoholic fatty liver disease
- 16 March 2023
- Published by Elsevier in JHEP Reports
- Vol. 5 (7) , 100730
Open AccessA greater ratio of thigh subcutaneous fat to abdominal fat is associated with protection against non-alcoholic fatty liver disease
- 17 November 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 196, 110163
Effect of changes in anthropometric measurements on the remission and progression of prediabetes: A community-based cohort study
- 17 November 2022
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 196, 110163
Effect of changes in anthropometric measurements on the remission and progression of prediabetes: A community-based cohort study
- Open Access
- 28 January 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (4) , 830-836
Osteocalcin and Risks of Incident Diabetes and Diabetic Kidney Disease: A 4.6-Year Prospective Cohort Study
OBJECTIVE: We aimed to examine the relationship between osteocalcin (OC) and the risk of incident diabetes and the risk of incident diabetic kidney disease (DKD). RESEARCH DESIGN AND METHODS: We followed 5,396 participants without diabetes (nondiabetes subcohort) and 1,174 participants with diabetes and normal kidney function (diabetes subcohort) at baseline. Logistic regression and modified Poisson regression models were used to estimate the relative risk (RR) of baseline OC levels with incident diabetes and DKD. RESULTS: During a mean 4.6-year follow-up period, 296 cases of incident diabetes and 184 cases of incident DKD were identified. In the nondiabetes subcohort, higher OC levels were linearly associated with a decreased risk of diabetes (RR for 1-unit increase of loge-transformed OC 0.51 [95% CI 0.35–0.76]; RR for highest vs. lowest quartile 0.65 [95% CI 0.44–0.95]; P for trend < 0.05). In the diabetes subcohort, OC levels were linearly inversely associated with incident DKD (RR for 1-unit increase of loge-transformed OC 0.49 [95% CI 0.33–0.74]; RR for highest vs. lowest quartile 0.56 [95% CI 0.38–0.83]; P for trend < 0.05), even independent of baseline estimated glomerular filtration rate and urinary albumin-to-creatinine ratio. No significant interactions between OC and various subgroups on incident diabetes or DKD were observed. CONCLUSIONS: Lower OC levels were associated with an increased risk of incident diabetes and DKD.
- 28 January 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (4) , 830-836
Open AccessOsteocalcin and Risks of Incident Diabetes and Diabetic Kidney Disease: A 4.6-Year Prospective Cohort Study
OBJECTIVE: We aimed to examine the relationship between osteocalcin (OC) and the risk of incident diabetes and the risk of incident diabetic kidney disease (DKD). RESEARCH DESIGN AND METHODS: We followed 5,396 participants without diabetes (nondiabetes subcohort) and 1,174 participants with diabetes and normal kidney function (diabetes subcohort) at baseline. Logistic regression and modified Poisson regression models were used to estimate the relative risk (RR) of baseline OC levels with incident diabetes and DKD. RESULTS: During a mean 4.6-year follow-up period, 296 cases of incident diabetes and 184 cases of incident DKD were identified. In the nondiabetes subcohort, higher OC levels were linearly associated with a decreased risk of diabetes (RR for 1-unit increase of loge-transformed OC 0.51 [95% CI 0.35–0.76]; RR for highest vs. lowest quartile 0.65 [95% CI 0.44–0.95]; P for trend < 0.05). In the diabetes subcohort, OC levels were linearly inversely associated with incident DKD (RR for 1-unit increase of loge-transformed OC 0.49 [95% CI 0.33–0.74]; RR for highest vs. lowest quartile 0.56 [95% CI 0.38–0.83]; P for trend < 0.05), even independent of baseline estimated glomerular filtration rate and urinary albumin-to-creatinine ratio. No significant interactions between OC and various subgroups on incident diabetes or DKD were observed. CONCLUSIONS: Lower OC levels were associated with an increased risk of incident diabetes and DKD.
- Top Cited PapersOpen Access
- 11 September 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (1) , 88-97
Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China
Context: In 2020, the terminology of metabolic dysfunction–associated fatty liver disease (MAFLD) was proposed to replace nonalcoholic fatty liver disease (NAFLD). Objectives: This work aimed to investigate the prevalence and incidence of MAFLD and evaluate its effects on incident extrahepatic diseases. Methods: A total of 6873 individuals, with a 4.6-year follow-up, were included in this study. Associations of MAFLD and NAFLD with diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD) were examined using logistic regression and Cox proportional hazards models. Results: The prevalence of NAFLD and MAFLD was 40.3% (95% CI, 39.2%-41.5%) and 46.7% (95% CI, 45.6%-47.9%), respectively. Additionally, 321 (4.7%) and 156 (2.3%) participants had MAFLD with excessive alcohol consumption and hepatitis B virus (HBV) infection. During the follow-up period, the incidence of NAFLD and MAFLD was 22.7% (95% CI, 21.3%-24.0%) and 27.0% (95% CI, 25.5%-28.4%). MAFLD was associated with higher risks of incident diabetes (risk ratio [RR] 2.08; 95% CI, 1.72-2.52), CKD (RR 1.64; 95% CI, 1.39-1.94), and CVD (hazard ratio 1.44; 95% CI, 1.15-1.81). Similar associations for NAFLD were observed. Furthermore, the MAFLD subgroups with excessive alcohol consumption (RR 2.49; 95% CI, 1.64-3.78) and HBV infection (RR 1.98; 95% CI, 1.11-3.52) were associated with higher risks of incident diabetes. Conclusion: The change from NAFLD to MAFLD did not greatly affect the associations with diabetes, CKD, and CVD. MAFLD further identified those patients of metabolically fatty liver combined with excessive alcohol consumption and HBV infection, who had increased risks of incident diabetes compared with those of non–fatty liver.
- 11 September 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (1) , 88-97
Top Cited PapersOpen AccessAssociation of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China
Context: In 2020, the terminology of metabolic dysfunction–associated fatty liver disease (MAFLD) was proposed to replace nonalcoholic fatty liver disease (NAFLD). Objectives: This work aimed to investigate the prevalence and incidence of MAFLD and evaluate its effects on incident extrahepatic diseases. Methods: A total of 6873 individuals, with a 4.6-year follow-up, were included in this study. Associations of MAFLD and NAFLD with diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD) were examined using logistic regression and Cox proportional hazards models. Results: The prevalence of NAFLD and MAFLD was 40.3% (95% CI, 39.2%-41.5%) and 46.7% (95% CI, 45.6%-47.9%), respectively. Additionally, 321 (4.7%) and 156 (2.3%) participants had MAFLD with excessive alcohol consumption and hepatitis B virus (HBV) infection. During the follow-up period, the incidence of NAFLD and MAFLD was 22.7% (95% CI, 21.3%-24.0%) and 27.0% (95% CI, 25.5%-28.4%). MAFLD was associated with higher risks of incident diabetes (risk ratio [RR] 2.08; 95% CI, 1.72-2.52), CKD (RR 1.64; 95% CI, 1.39-1.94), and CVD (hazard ratio 1.44; 95% CI, 1.15-1.81). Similar associations for NAFLD were observed. Furthermore, the MAFLD subgroups with excessive alcohol consumption (RR 2.49; 95% CI, 1.64-3.78) and HBV infection (RR 1.98; 95% CI, 1.11-3.52) were associated with higher risks of incident diabetes. Conclusion: The change from NAFLD to MAFLD did not greatly affect the associations with diabetes, CKD, and CVD. MAFLD further identified those patients of metabolically fatty liver combined with excessive alcohol consumption and HBV infection, who had increased risks of incident diabetes compared with those of non–fatty liver.